Circulating tumor DNA (ctDNA) dynamics and clinical outcome in metastatic colorectal cancer (mCRC) patients (pts) undergoing front-line chemotherapy

被引：0
|
作者：
Ghidini, M. [1 ]
Hahne, J. C. [2 ]
Senti, C. [3 ]
Tomasello, G. [1 ]
Ratti, M. [3 ]
Heide, T. [4 ]
Garrone, O. [1 ]
Cortellini, A. [5 ]
Passalacqua, R. [3 ]
Valeri, N. [5 ]
机构：
[1] Fdn IRCCS Osped Maggiore Policlin, Oncol Unit, Milan, Italy
[2] ICR, Ctr Mol Pathol, London, England
[3] ASST Cremona Azienda Sociosanitaria Terr, Oncol Unit, Cremona, Italy
[4] Human Technopole, Computat Biol Res Ctr, Milan, Italy
[5] Imperial Coll London, Dept Surg & Canc, London, England
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.1355
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2326P
引用
收藏
页码：S1188 / S1188
页数：1
相关论文
共 50 条
  • [21] RAS mutations in circulating tumor DNA (ctDNA) and clinical outcomes of rechallenge treatments with anti-EGFR antibodies n patients with metastatic colorectal cancer (mCRC)
    Sunakawa, Y.
    Nakamura, M.
    Ishizaki, M.
    Kataoka, M.
    Satake, H.
    Kitazono, M.
    Yanagisawa, H.
    Kawamoto, Y.
    Kuramochi, H.
    Ohori, H.
    Nakamura, M.
    Takahashi, K.
    Maeda, F.
    Komeno, C.
    Takeuchi, M.
    Fujii, M.
    Yoshino, T.
    Ichikawa, W.
    Tsuji, A.
    ANNALS OF ONCOLOGY, 2019, 30 : 114 - 114
  • [22] Genomic profiling of circulating tumor DNA (ctDNA) from patients (pts) with metastatic breast cancer (mBC).
    Pusztai, Lajos
    Chung, Jon
    Young, Lauren
    Schrock, Alexa Betzig
    Hartmaier, Ryan
    Frampton, Garrett Michael
    Gay, Laurie M.
    Stephens, Phil
    Miller, Vincent A.
    Ali, Siraj Mahamed
    Ross, Jeffrey S.
    Vahdat, Linda T.
    O'Shaughnessy, Joyce
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [23] Front-line use of FOLFOXIRI plus bevacizumab and subsequent therapies in metastatic colorectal cancer (mCRC).
    Barzi, Afsaneh
    Lunacsek, Orsolya
    Pisa, Federica
    Pan, Xiaoyun
    Ostojic, Helene
    Vassilev, Zdravko
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 45 - 45
  • [24] Clinical utility of serial circulating tumor DNA (ctDNA) to identify acquired resistance to anti-EGFR antibodies in metastatic colorectal cancer (mCRC).
    Loree, Jonathan M.
    Bubie, Adrian
    Eluri, Madhulika
    Parseghian, Christine Megerdichian
    Overman, Michael J.
    Zhang, Nicole
    Drusbosky, Leylah
    Kopetz, Scott
    Raghav, Kanwal Pratap Singh
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 158 - 158
  • [25] Circulating tumor DNA dynamics on front-line chemotherapy with bevacizumab or cetuximab in metastatic colorectal cancer: A biomarker analysis for acquired genomic alterations in CALGB/SWOG 80405 (Alliance) randomized trial
    Raghav, Kanwal Pratap Singh
    Ou, Fang-Shu
    Venook, Alan P.
    Innocenti, Federico
    Sun, Ryan
    Lenz, Heinz-Josef
    Kopetz, Scott
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [26] Clinical application of circulating tumor DNA (ctDNA) in patients with metastatic gastric cancer.
    Hong, Moonki
    Lee, Kwang Seob
    Park, Sejung
    Kim, Kyoo Hyun
    Kim, Hyunwook
    Che, Jingmin
    Kwon, Woo Sun
    Lee, Choong-kun
    Jung, Minkyu
    Chung, Hyun Cheol Cheol
    Shin, Saeam
    Lee, Seung-Tae
    Choi, Jong Rak
    Rha, Sun Young
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 441 - 441
  • [27] Does serial circulating tumor DNA (ctDNA) monitoring identify additional acquired actionable alterations in metastatic colorectal cancer (mCRC)?
    Loree, Jonathan M.
    Bubie, Adrian
    Strickler, John H.
    Drusbosky, Leylah
    Kopetz, Scott
    Raghav, Kanwal Pratap Singh
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [28] Loco-Regional Treatment of the Primary Tumor in De Novo Metastatic Breast Cancer Patients Undergoing Front-Line Chemotherapy
    Tinterri, Corrado
    Sagona, Andrea
    Barbieri, Erika
    Di Maria Grimaldi, Simone
    Jacobs, Flavia
    Zambelli, Alberto
    Trimboli, Rubina Manuela
    Bernardi, Daniela
    Vinci, Valeriano
    Gentile, Damiano
    CANCERS, 2022, 14 (24)
  • [29] Serial circulating tumor DNA (ctDNA) monitoring in metastatic colorectal cancer (mCRC) reveals dynamic profile of actionable alterations.
    Loree, Jonathan M.
    Henry, Jason
    Raghav, Kanwal Pratap Singh
    Parseghian, Christine Megerdichian
    Banks, Kimberly
    Raymond, Victoria M.
    Nagy, Rebecca
    Hensel, Chuck
    Strickler, John H.
    Corcoran, Ryan Bruce
    Overman, Michael J.
    Talasaz, AmirAli
    Kopetz, Scott
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [30] Prognostic factors of patients (pts) with salvage-line metastatic colorectal cancer (mCRC)
    Bando, Hideaki
    Oki, Eiji
    Takeda, Yuriko
    Misumi, Toshihiro
    Suzuki, Motoko
    Wakabayashi, Masashi
    Yamazaki, Kentaro
    Grothey, Axel
    Mayer, Robert J.
    Li, Jin
    Andre, Thierry
    Shi, Qian
    De Gramont, Aimery
    Yoshino, Takayuki
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 115 - 115
12345